Carrazana Enrique, Mikoshiba Imao
Neuroscience, Clinical Development and Medical Affairs, Novartis Pharmaceuticals, East Hanover, NJ 07936-1080, USA.
J Pain Symptom Manage. 2003 May;25(5 Suppl):S31-5. doi: 10.1016/s0885-3924(03)00067-8.
Oxcarbazepine is a second-generation antiepileptic drug (AED) with proven efficacy in managing partial epileptic seizures, with or without secondary generalization, in adults and children. The overlap between the underlying pathophysiologic mechanisms of some epilepsy models and neuropathic pain models supports the rationale for using certain AEDs in the treatment of neuropathic pain. Several AEDs have reportedly produced analgesia in a range of neuropathic pains, including painful diabetic neuropathy (PDN) and post-herpetic neuralgia. Increasing evidence suggests that oxcarbazepine can provide significant analgesia in several neuropathic pain conditions, including trigeminal neuralgia and PDN, and is also may be effective in treating neuropathic pain refractory to other AEDs, such as carbamazepine and gabapentin. The analgesic effects of oxcarbazepine, and its generally improved safety and tolerability profile compared with other standard AEDs, suggests that oxcarbazepine will be an important addition to the neuropathic pain armamentarium. The rationale and evidence to support the efficacy of oxcarbazepine are presented here.
奥卡西平是一种第二代抗癫痫药物(AED),在治疗成人和儿童的部分性癫痫发作(不论是否继发全面性发作)方面已证实具有疗效。一些癫痫模型和神经性疼痛模型的潜在病理生理机制存在重叠,这为使用某些抗癫痫药物治疗神经性疼痛提供了理论依据。据报道,几种抗癫痫药物在一系列神经性疼痛中都产生了镇痛作用,包括糖尿病性神经痛(PDN)和带状疱疹后神经痛。越来越多的证据表明,奥卡西平在包括三叉神经痛和糖尿病性神经痛在内的几种神经性疼痛病症中能提供显著的镇痛作用,并且在治疗对其他抗癫痫药物(如卡马西平和加巴喷丁)难治的神经性疼痛方面也可能有效。与其他标准抗癫痫药物相比,奥卡西平的镇痛作用及其总体上改善的安全性和耐受性表明,奥卡西平将成为神经性疼痛治疗药物库中的重要补充。本文介绍了支持奥卡西平疗效的理论依据和证据。